The National Medical Products Administration conditionally approves the marketing of Famiciribine capsules.

Recently, the National Medical Products Administration conditionally approved Jiangsu Hengrui Medicine Co., Ltd.'s application for a type 1 innovative drug, fumitremorgin A capsules, which, in combination with injection of camrelizumab, is used for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with pembrolizumab. The approval of this drug provides patients with a new treatment option.